Literature DB >> 16217180

Update on the Burkholderia cepacia complex.

John J Lipuma1.   

Abstract

PURPOSE OF REVIEW: The Burkholderia cepacia complex is comprised of a group of related bacterial species that are capable of causing life-threatening respiratory tract infection in persons with cystic fibrosis. This article reviews advances in our understanding of Burkholderia cepacia complex infection in cystic fibrosis, focusing on the taxonomy, clinical microbiology, and epidemiology, as well as the natural history and clinical outcomes associated with Burkholderia cepacia complex infection. RECENT
FINDINGS: Each of the nine species of the Burkholderia cepacia complex has now received a formal species name. These names are the preferred nomenclature, replacing the former 'genomovar' designations. Studies from several countries reiterate that two species, Burkholderia cenocepacia and Burkholderia multivorans, account for most Burkholderia cepacia complex infection in cystic fibrosis. Bacterial genotyping studies indicate that specific Burkholderia cepacia complex strains infect multiple cystic fibrosis patients, implying that they may have an enhanced capacity for interpatient spread. Emerging clinical outcomes data suggest that at least some of these so-called transmissible or epidemic strains are also more virulent in the cystic fibrosis host. Ongoing research is aimed at gaining a better understanding of Burkholderia cepacia complex ecology, defining Burkholderia cepacia complex virulence factors and pathogenic mechanisms, and determining the relative virulence of distinct strains.
SUMMARY: Significant advances in our understanding of the Burkholderia cepacia complex serve as a critical foundation for further efforts that ultimately will enable better infection control and the development of novel therapeutics to treat Burkholderia cepacia complex infection in persons with cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16217180     DOI: 10.1097/01.mcp.0000181475.85187.ed

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  64 in total

1.  Vaccine strategies against cystic fibrosis pathogens.

Authors:  Vincent Le Moigne; Jean-Louis Gaillard; Jean-Louis Herrmann
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

2.  Burkholderia cenocepacia ZmpB is a broad-specificity zinc metalloprotease involved in virulence.

Authors:  C Kooi; B Subsin; R Chen; B Pohorelic; P A Sokol
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

3.  Revised approach for identification of isolates within the Burkholderia cepacia complex and description of clinical isolates not assigned to any of the known genomovars.

Authors:  Jane F Turton; Nazia Arif; Daneeta Hennessy; Mary E Kaufmann; Tyrone L Pitt
Journal:  J Clin Microbiol       Date:  2007-07-11       Impact factor: 5.948

4.  Cystic fibrosis, a Burkholderia cenocepacia chest wall abscess and rapid clinical deterioration.

Authors:  N J Simmonds; K M Gyi
Journal:  J R Soc Med       Date:  2008-07       Impact factor: 5.344

5.  Multi-center evaluation of the VITEK® MS system for mass spectrometric identification of non-Enterobacteriaceae Gram-negative bacilli.

Authors:  R Manji; M Bythrow; J A Branda; C-A D Burnham; M J Ferraro; O B Garner; R Jennemann; M A Lewinski; A B Mochon; G W Procop; S S Richter; J A Rychert; L Sercia; L F Westblade; C C Ginocchio
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-10       Impact factor: 3.267

6.  An outbreak of Burkholderia cenocepacia bacteremia in immunocompromised oncology patients.

Authors:  T Mann; D Ben-David; A Zlotkin; D Shachar; N Keller; A Toren; A Nagler; G Smollan; A Barzilai; G Rahav
Journal:  Infection       Date:  2010-04-01       Impact factor: 3.553

7.  Diversity and evolution of the phenazine biosynthesis pathway.

Authors:  Dmitri V Mavrodi; Tobin L Peever; Olga V Mavrodi; James A Parejko; Jos M Raaijmakers; Philippe Lemanceau; Sylvie Mazurier; Lutz Heide; Wulf Blankenfeldt; David M Weller; Linda S Thomashow
Journal:  Appl Environ Microbiol       Date:  2009-12-11       Impact factor: 4.792

8.  Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection.

Authors:  Lisa A Carmody; Jason J Gill; Elizabeth J Summer; Uma S Sajjan; Carlos F Gonzalez; Ryland F Young; John J LiPuma
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

9.  Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine.

Authors:  P E Makidon; J Knowlton; J V Groom; L P Blanco; J J LiPuma; A U Bielinska; J R Baker
Journal:  Med Microbiol Immunol       Date:  2009-12-06       Impact factor: 3.402

10.  In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species.

Authors:  John J LiPuma; Sivaprakash Rathinavelu; Bridget K Foster; Jordan C Keoleian; Paul E Makidon; Linda M Kalikin; James R Baker
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.